Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for dermal injections used to treat facial lipodystrophy syndrome, with an effective date of May 15, 2026. Here's what billing teams need to know before that date.
CMS facial lipodystrophy dermal injection coverage has a specific history — this isn't a brand-new policy area, but a modification signals that criteria, documentation requirements, or covered indications have shifted. The full source document is available at the PayerPolicy source link. No specific policy code applies to this change. The policy does not list specific CPT or HCPCS codes in the data provided to us — we'll address that directly in the codes section below.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Dermal Injections for the Treatment of Facial Lipodystrophy Syndrome (LDS) |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium — affects a defined patient population but requires documentation precision |
| Specialties Affected | Infectious disease, plastic surgery, dermatology, HIV medicine |
| Key Action | Audit your documentation and prior authorization workflows for facial lipodystrophy dermal injection claims before May 15, 2026 |
CMS Facial Lipodystrophy Dermal Injection Coverage Criteria and Medical Necessity Requirements 2026
Facial lipodystrophy syndrome is a real condition with real billing stakes. It causes fat loss in the face — particularly in the cheeks, temples, and around the eyes — most commonly in patients with HIV who have taken antiretroviral therapy. The Centers for Medicare & Medicaid Services has covered dermal injections to treat this condition under specific medical necessity criteria, and this modification means those criteria have changed.
CMS draws a clear line between cosmetic procedures and medically necessary treatment. That line matters enormously for reimbursement. Facial lipodystrophy dermal injections fall on the covered side of that line — but only when documented correctly and tied to a qualifying diagnosis. If your documentation doesn't reflect the specific condition and its connection to antiretroviral therapy, you're at serious risk of claim denial.
Medical necessity for facial lipodystrophy treatment under CMS has historically required evidence that the fat loss results from antiretroviral drug therapy, not from aging or other causes. The patient's HIV status and treatment history are central to the justification. Your clinical notes need to make that connection explicitly — not implicitly.
This coverage policy modification may tighten or clarify those criteria. Because the detailed policy text wasn't available in the data provided, we recommend pulling the full document directly from the CMS source and reading it line by line before May 15, 2026. If you're unsure how the updated criteria map to your patient mix, talk to your compliance officer before the effective date.
Prior authorization requirements for dermal injections under Medicare vary by Medicare Administrative Contractor. Check with your MAC to confirm whether prior auth is required in your region under the updated policy. Don't assume the requirements haven't changed just because they didn't change last time.
CMS Facial Lipodystrophy Dermal Injection Exclusions and Non-Covered Indications
CMS has consistently excluded dermal injections performed for purely cosmetic purposes — meaning procedures where the clinical indication is aesthetic improvement rather than treatment of medically documented lipodystrophy. This distinction isn't new, but it's worth stating plainly: the diagnosis code on your claim has to match the condition, not the procedure.
Injections for age-related facial volume loss, facial asymmetry unrelated to lipodystrophy, or general cosmetic augmentation are not covered. Billing a dermal injection with a lipodystrophy diagnosis code when the clinical record doesn't support that diagnosis is a documentation problem that creates both a claim denial risk and a compliance risk.
The specific exclusions under the modified policy should be confirmed against the full CMS document. If this modification added new exclusions or narrowed existing covered indications, your billing team needs to know before claims go out after May 15, 2026.
Coverage Indications at a Glance
The policy data provided does not include the full text of the modified criteria, so the table below reflects what CMS has historically applied to this coverage area. Confirm each row against the updated policy document before May 15, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Facial lipodystrophy caused by antiretroviral therapy in HIV+ patients | Covered (when criteria met) | Not specified in policy data | Medical necessity documentation required; HIV treatment history must be in record |
| Cosmetic facial augmentation (no lipodystrophy diagnosis) | Not Covered | Not specified in policy data | Not a medical necessity; will trigger claim denial |
| Facial volume loss from aging or other non-drug causes | Not Covered | Not specified in policy data | Must distinguish from LDS in documentation |
| Repeat injections without documented ongoing medical necessity | Status unclear — verify against updated policy | Not specified in policy data | Talk to your compliance officer if your patients receive repeat treatment cycles |
CMS Facial Lipodystrophy Dermal Injection Billing Guidelines and Action Items 2026
Here's what your billing team should do before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the full updated CMS policy document now. The source is at app.payerpolicy.org/p/cms/338-v1. Read it against your current documentation templates and charge capture workflows. Don't rely on this blog post alone — the specific modified language matters. |
| 2 | Audit your active patient files for facial lipodystrophy billing. Identify every patient where you're billing dermal injections for LDS. Review their records to confirm HIV diagnosis, antiretroviral treatment history, and clinical documentation of lipodystrophy. Every claim after May 15, 2026 needs to reflect the updated criteria. |
| 3 | Confirm your MAC's prior authorization requirements. Medicare Administrative Contractor rules vary by region. Facial lipodystrophy dermal injection billing guidelines may include prior auth requirements that differ between contractors. Call your MAC or check their LCD database if one applies to this service in your region. |
| 4 | Update your documentation templates before May 15, 2026. If the modified coverage policy adds new documentation requirements — clinical criteria, treatment history, or physician attestation — your intake and visit documentation templates need to reflect that. Don't let your physicians continue using templates that were built for the old criteria. |
| 5 | Train your coding staff on the distinction between covered and non-covered indications. Facial lipodystrophy billing is one of those areas where the diagnosis code selection is everything. Your coders need to understand that a dermal injection with a cosmetic indication is a denied claim. An injection with a properly documented lipodystrophy diagnosis tied to antiretroviral therapy is a covered claim. That distinction should be in your coding education materials. |
| 6 | Check for any changes to the applicable HCPCS or CPT codes. The policy data we have does not list specific procedure codes. CMS may have added or removed codes in the modification. Confirm this against the full policy document and update your charge capture accordingly. |
| 7 | Talk to your compliance officer if you have high volume in this area. If your practice or facility treats a significant number of HIV patients and has substantial facial lipodystrophy dermal injection billing, a compliance review of your claims history is worth doing before the effective date. This is especially true if your denial rate in this category has been elevated. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Facial Lipodystrophy Dermal Injections Under This CMS Policy
The policy data provided for this modification does not list specific CPT, HCPCS, or ICD-10 codes. We do not fabricate codes.
This is important for your billing team to understand. It means you need to go directly to the full CMS policy document to confirm which procedure codes are covered under the updated criteria. Facial lipodystrophy dermal injection billing has historically involved HCPCS codes for injectable fillers — but those codes, their coverage status, and any applicable quantity limits must be confirmed from the source document, not assumed from prior versions of the policy.
Pull the current code list from the full policy at app.payerpolicy.org/p/cms/338-v1. Cross-reference against your charge master. If codes were added, removed, or had their coverage status changed in this modification, your charge capture needs to reflect that before May 15, 2026.
If you're subscribed to PayerPolicy, the version diff tool will show you exactly which codes changed between the prior version and this one — line by line.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.